

Pharmaceutical Surface Science: A potential way forward!



Dr Robert Price

University of Bath,
Pharmaceutical Technology Research Group.
r.price@bath.ac.uk

Synopsis


- Introduction
- AFM Studies
 - Adhesion Force Measurements
 - Characterisation of Amorphous domains
 - Surface Stability of Amorphous domains
- Conclusions
- Acknowledgments

Why is surface characterisation important?

- Pharmaceutical processes involve interfacial contact.
- A change in surface nature will affect interfacial interactions.
- The success or failure of a formulation is dependant on the nature of the surfaces.

What influences the surface properties of powders?

- Presence of different crystal habits
- A change in polymorphic form
- **Presence of amorphous material**





Colloid interactions in air

Particle interactions are primarily dictated by:

- I. van der Waals Forces (LW and AB)
- II. Electrostatic Forces
- III. Capillary Forces

The relative contribution of forces (II.) and (III.) to the total adhesion/cohesion depends on the interacting materials and relative humidity.

Colloidal Interactions in solution

Extended DLVO Theory

- Lifshitz-van der Waals Interaction
- Electrostatic double layer forces
- Lewis acid/base interaction
 - Hydrogen bonding
 - Hydrophobic interaction
- Steric interaction
 - Entropic contribution
 - Osmotic contribution

DLVO Theory

Additional factors that influence particle adhesion

Surface Energy	-	Intrinsic "free" energy
Surface Roughness	-	Contact Area
Mechanical Properties	-	Hardness
Environmental Conditions	-	Temp. & %RH

i. Smooth Surface ii. $\phi_d > B$ iii. $\phi_d < B$







Atomic Force Microscope (AFM)

Model salbutamol sulphate drug probe

$F = kdx$ $k = \text{spring constant (N/m)}$
 $dx = \text{cantilever deflection}$

In-situ AFM set-up

- Hermetically sealed system.
- Potential for high vapour pressure propellant studies.
- Forces and surface stability measurements.





Conclusion (1)

- AFM provides a fundamental insight into the microscopic interactions which govern bulk properties of a DPI formulation.
- Variation in excipient surface roughness at the nanometre-Angstrom scale dramatically influences drug-lactose interactions.
- Controlling surface roughness of excipient surfaces may lead to increased fine particle delivery.

Can the surface roughness of commercial grade lactose be controllably modified?


UoB surface engineered Lactose




$$\% \sigma_{\text{under}} = - \frac{C_T - C_S}{C_S} \times 100$$

$$\% M_{\text{etched}} = - \frac{C_T - C_S}{M_{\text{added}}} \times 100$$

Patent Pending




The effect of etching conditions on %FPF



- Salbutamol Sulphate:Lactose (1 : 67.5 %w/w) blend
- In vitro apparatus: TSI @ 60 L/min (cut-off $d_{50} = 6.4 \mu\text{m}$).
- Cyclohaler device (n = 10)

Crystalline vs. Processed



Generation of Amorphous regions







- Thermodynamically metastable
- Physico-chemical instability
- Irreversible changes to a formulation







Is a few % amorphous content important?

If all at the surface!

- Altered interfacial interactions
- Change in product properties
- Batch-to-batch variation

How do we measure the nature of processed powder surfaces?







Conclusion



- The presence and molecular mobility of amorphous regions will adversely affect the stability and characteristics of a DPI formulation.
- Development of new methodologies are required in the conditioning and processing of inhalation drug products

SEDS: A potential long term solution ?

SEDS produced Salbutamol Sulphate





SEDS produced Salbutamol Sulphate




Interfacial interactions and stability may remain an issue ?

Constructive particle production wish-list


- High purity micron sized particles
- Defined morphological structures (spherical preferred)
- Defined surface structure (nanometre asperities)
- Single step operation with a dial-up particle size input
- Physico-chemical stable particles
- Controlled physico-chemical properties (surface energy)



Conventionally processed material




As supplied Paracetamol



Micronised Paracetamol

SAXS produced paracetamol particles




1% w/w


5% w/w

10% w/w


Ethanol
5.8 kPa




Methanol
12.3 kPa




Acetone
24.0 kPa




Stability of micronised and SAXS produced budesonide particles in a HFA pMDI



5 sec 15 sec 30 sec 60 sec 120 sec 300 sec



Micronised Budesonide



SAXS produced Budesonide


Extended dispersion testing



5 sec 10 min 30 min 60 min 120 min 5 hr 10 hr



in-vitro ACI deposition behaviour



- Model budesonide formulations in HFA-227 (100µg dose)
- In vitro apparatus: ACI @ 28.3 L/min
- No significant difference in %FPF and Delivered Dose

General Conclusions



The AFM can be used, in real time, to characterise:

- Adhesive characteristics of particulate materials.
- Physical transformations on particle surfaces.
- Thermodynamically metastable amorphous domains, at a nanometre level.
- Long term stability of the powdered systems.

General Conclusions



- In combination with bulk techniques, AFM may potentially play a pivotal role in the design and modifications of DPI and suspension based formulations.
- There is a further need to correlate:
 - Relationship between surface thermodynamics (contact angles, IGC), force measurements (AFM, CPD) and *in vitro* performance.
 - Macroscopic properties of surfaces and meso scale properties of interfacial interactions and related adhesion.

Acknowledgements



Sebastian Kaersyer
Phillippe Bagat
Daniela Traini
Jim Thompson
Dina El-Sabawi
Dr. Asha Katilga
Dr. Paul Young
Dr. Stephen Edge
Dr. Fraser Steele

100µm